1h Free Analyst Time
The gastroesophageal reflux disease (GERD) market is forecast to grow by USD 879.8 million during 2023-2028, accelerating at a CAGR of 3.2% during the forecast period. The report on the gastroesophageal reflux disease (GERD) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising geriatric population, poor lifestyle patterns, and overuse of medicines and dietary supplements.
The gastroesophageal reflux disease (GERD) market is segmented as below:
By Route Of Administration
- Oral
- Parenteral
By Type
- Antacid
- PPI
- H2 receptor antagonist drugs
- Pro-Kinetic drugs
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the gastroesophageal reflux disease (GERD) market covers the following areas:
- Gastroesophageal reflux disease (GERD) market sizing
- Gastroesophageal reflux disease (GERD) market forecast
- Gastroesophageal reflux disease (GERD) market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global gastroesophageal reflux disease (GERD) market: Abbott Laboratories, Alkem Laboratories Ltd., Apotex Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, inovapharma.com, Johnson and Johnson Services Inc., Lupin Ltd., Perrigo Co. Plc, Pfizer Inc., SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and The Procter and Gamble Co..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is rising prevalence of obesity."
According to the report, one of the major drivers for this market is the rising geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Alkem Laboratories Ltd.
- Apotex Inc.
- AstraZeneca Plc
- Aurobindo Pharma Ltd.
- Bayer AG
- Cipla Inc.
- Dr Reddys Laboratories Ltd.
- Eisai Co. Ltd.
- Fresenius SE and Co. KGaA
- GlaxoSmithKline Plc
- inovapharma.com
- Johnson and Johnson Services Inc.
- Lupin Ltd.
- Perrigo Co. Plc
- Pfizer Inc.
- SRS Life Sciences Pte. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- The Procter and Gamble Co.
